Vasopressin in liver disease - Should we turn on or off?

Current Clinical Pharmacology

Volumn 3, Issue 3, 2008, Pages 156-165

  Lo, Robert ^a   Austin, Andrew ^a   Freeman, Jan ^a  

^a DERBY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 [1 [4 (3 ACETAMIDOPROPOXY)BENZOYL] 4 PIPERIDYL] 1,2,3,4 TETRAHYDRO 2 QUINOLINONE; ALDOSTERONE; ANGIOTENSIN; ANTIBIOTIC AGENT; ARGIPRESSIN; CONIVAPTAN; FUROSEMIDE; GLYCERYL TRINITRATE; LIXIVAPTAN; MOZAVAPTAN; NITRIC OXIDE; ORNIPRESSIN; PLACEBO; RELCOVAPTAN; RENIN; RWJ 351647; SATAVAPTAN; SODIUM; SORAFENIB; SPIRONOLACTONE; TERLIPRESSIN; TOLVAPTAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOPRESSIN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V1B RECEPTOR; VASOPRESSIN V2 RECEPTOR; WATER; VASOPRESSIN RECEPTOR;

ALCOHOL LIVER DISEASE; AMINO ACID COMPOSITION; ARTERIAL PRESSURE; ASCITES; BACTERIAL PERITONITIS; CHRONIC LIVER DISEASE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGUS VARICES BLEEDING; HEART INFARCTION; HEPATORENAL SYNDROME; HUMAN; HYPONATREMIA; HYPOVOLEMIA; INTESTINE ISCHEMIA; LIVER BLOOD FLOW; LIVER BLOOD VESSEL; LIVER CIRRHOSIS; PARACENTESIS; PERIPHERAL EDEMA; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; REVIEW; SEPTIC SHOCK; SIDE EFFECT; SINGLE DRUG DOSE; SODIUM RETENTION; TREATMENT DURATION; VASCULAR RESISTANCE; VASOCONSTRICTION; WATER RETENTION; ANIMAL; CHRONIC KIDNEY FAILURE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; HEMODYNAMICS; LIVER DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ARGININE VASOPRESSIN; HEMODYNAMICS; HUMANS; HYPERTENSION, PORTAL; HYPONATREMIA; KIDNEY FAILURE, CHRONIC; LIVER DISEASES; RECEPTORS, VASOPRESSIN;

EID: 58149131962     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488408785747728     Document Type: Review

References (101)

1. Bichet D, Szatalowicz V, Chaimovitz C, Schrier RW. Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann Intern Med 1982; 96: 413-7.
2. Gines P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987; 7: 122-8.
3. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995; 22: 332-54.
4. D'Amico G, Luca A. Natural history. Clinical-haemodynamic correlations. Prediction of the risk of bleeding. Baillieres Clin Gastroenterol 1997; 11: 243-56.
5. Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005; 353: 2254-61.
6. Robinson AG, Fitzsimmons MD. Vasopressin homeostasis: coordination of synthesis, storage and release. Regul Pept 1993; 45: 225-30.
7. Acher R. Neurohypophysial peptide systems: processing machinery, hydroosmotic regulation, adaptation and evolution. Regul Pept 1993; 45: 1-13.
8. Pesaturo AB, Jennings HR, Voils SA. Terlipressin: vasopressin analog and novel drug for septic shock. Ann Pharmacother 2006; 40: 2170-7.
9. Birnbaumer M. Vasopressin receptors. Trends Endocrinol Metab 2000; 11: 406-10.
10. Serradeil-le Gal C, Wagnon J, Valette G, et al. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res 2002; 139: 197-210.
11. Cavarape A, Bauer J, Bartoli E, Endlich K, Parekh N. Effects of angiotensin II, arginine vasopressin and tromboxane A2 in renal vascular bed: role of rho-kinase. Nephrol Dial Transplant 2003; 18: 1764-9.
12. Bauer J, Parekh N. Variations in cell signaling pathways for different vasoconstrictor agonists in renal circulation of the rat. Kidney Int 2003; 63: 2178-86.
13. Somlyo AP, Somlyo AV. Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J Physiol 2000; 522 (Pt 2): 177-85.
14. Knepper MA. Molecular physiology of urinary concentrating mechanism: regulation of aquaporin water channels by vasopressin. Am J Physiol 1997; 272: F3-12.
15. Nielsen S, Fror J, Knepper MA. Renal aquaporins: key roles in water balance and water balance disorders. Curr Opin Nephrol Hypertens 1998; 7: 509-16.
16. Bernat A, Hoffmann P, Dumas A, Serradeil-le Gal C, Raufaste D, Herbert JM. V2 receptor antagonism of DDAVP-induced release of hemostasis factors in conscious dogs. J Pharmacol Exp Ther 1997; 282: 597-602.
17. Brunton LL, Lazo JS, Parker KL. Goodman & Gilman's. The pharmacological basis of therapeutics, 11th ed, McGraw-Hill Medical Publishing, New York, 2006.
18. Shibayama Y, Nakata K. Localization of increased hepatic vascular resistance in liver cirrhosis. Hepatology 1985; 5: 643-8.
19. Orrego H, Medline A, Blendis LM, Rankin JG, Kreaden DA. Collagenisation of the Disse space in alcoholic liver disease. Gut 1979; 20: 673-9.
20. Bhathal PS, Grossman HJ. Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol 1985; 1: 325-37.
21. Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 2002; 35: 478-91.
22. Gupta TK, Toruner M, Chung MK, Groszmann RJ. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology 1998; 28: 926-31.
23. Hennenberg M, Stark C, Trebicka J, Sauerbruch T, Heller J. Effects of the multikinase inhibitor, Sorafenib, on portal pressure, hyperdynamic circulation, aortic contractility, and dysregulated Rho-kinase in rats with secondary biliary cirrhosis. J Hepatol 2008; 48: S38.
24. Hennenberg M, Biecker E, Trebicka J, et al. Defective RhoA/ Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats. Gastroenterology 2006; 130: 838-54.
25. Zhou Q, Hennenberg M, Trebicka J, et al. Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis. Gut 2006; 55: 1296-305.
26. Gonzalez-Abraldes J, Garcia-Pagan JC, Bosch J. Nitric oxide and portal hypertension. Metab Brain Dis 2002; 17: 311-24.
27. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56: 1310-8.
28. Castro A, Jimenez W, Claria J, et al. Impaired responsiveness to angiotensin II in experimental cirrhosis: role of nitric oxide. Hepatology 1993; 18: 367-72.
29. Sieber CC, Lopez-Talavera JC, Groszmann RJ. Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats. Gastroenterology 1993; 104: 1750-4.
30. Sieber CC, Groszmann RJ. In vitro hyporeactivity to methoxamine in portal hypertensive rats: reversal by nitric oxide blockade. Am J Physiol 1992; 262: G996-1001.
31. Lee FY, Albillos A, Colombato LA, Groszmann RJ. The role of nitric oxide in the vascular hyporesponsiveness to methoxamine in portal hypertensive rats. Hepatology 1992; 16: 1043-8.
32. Llach J, Gines P, Arroyo V, et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988; 94: 482-7.
33. Bosch J, Abraldes JG, Groszmann R. Current management of portal hypertension. J Hepatol 2003; 38 (Suppl 1): S54-S68.
34. Hori N, Okanoue T, Mori T, et al. Endogenous nitric oxide production is augmented as the severity advances in patients with liver cirrhosis. Clin Exp Pharmacol Physiol 1996; 23: 30-5.
35. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 1151-7.
36. Laffi G, Lagi A, Cipriani M, et al. Impaired cardiovascular autonomic response to passive tilting in cirrhosis with ascites. Hepatology 1996; 24: 1063-7.
37. Moller S, Iversen JS, Henriksen JH, Bendtsen F. Reduced baroreflex sensitivity in alcoholic cirrhosis: relations to hemodynamics and humoral systems. Am J Physiol Heart Circ Physiol 2007; 292: H2966-H2972.
38. Moller S, Wiinberg N, Hernriksen JH. Noninvasive 24-hour ambulatory arterial blood pressure monitoring in cirrhosis. Hepatology 1995; 22: 88-95.
39. Merli M, Nicolini G, Angeloni S, et al. Incidence and natural history of small esophageal varices in cirrhotic patients. J Hepatol 2003; 38: 266-72.
40. D'Amico G, De Franchis R. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology 2003; 38: 599-612.
41. Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105: 229-36.
42. Arroyo V, Terra C, Gines P. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. J Hepatol 2007; 46: 935-46.
43. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 2006; 43: S121-S131.
44. Dagher L, Moore K. The hepatorenal syndrome. Gut 2001; 49: 729-37.
45. Arroyo V, Guevara M, Gines P. Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology 2002; 122: 1658-76.
46. Alessandria C, Ozdogan O, Guevara M, et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology 2005; 41: 1282-9.
47. Conn HO, Ramsby GR, Storer EH, et al. Intraarterial vasopressin in the treatment of upper gastrointestinal hemorrhage: a prospective, controlled clinical trial. Gastroenterology 1975; 68: 211-21.
48. Mallory A, Schaefer JW, Cohen JR, Holt SA, Norton LW. Selective intra-arterial vasopression in fusion for upper gastrointestinal tract hemorrhage: a controlled trial. Arch Surg 1980; 115: 30-2.
49. Merigan TC, Jr., Plotkin GR, Davidson CS. Effect of intravenously administered posterior pituitary extract on hemorrhage from bleeding esophageal varices. A controlled evaluation. N Engl J Med 1962; 266: 134-5.
50. Fogel MR, Knauer CM, Andres LL, et al. Continuous intravenous vasopressin in active upper gastrointestinal bleeding. Ann Intern Med 1982; 96: 565-9.
51. Bosch J, Groszmann RJ, Garcia-Pagan JC, et al. Association of transdermal nitroglycerin to vasopressin infusion in the treatment of variceal hemorrhage: a placebo-controlled clinical trial. Hepatology 1989; 10: 962-8.
52. Tsai YT, Lay CS, Lai KH, et al. Controlled trial of vasopressin plus nitroglycerin vs. vasopressin alone in the treatment of bleeding esophageal varices. Hepatology 1986; 6: 406-9.
53. Westaby D, Gimson A, Hayes PC, Williams R. Haemodynamic response to intravenous vasopressin and nitroglycerin in portal hypertension. Gut 1988; 29: 372-7.
54. Nilsson G, Lindblom P, Ohlin M, Berling R, Vernersson E. Pharmacokinetics of terlipressin after single i.v. doses to healthy volunteers. Drugs Exp Clin Res 1990; 16: 307-14.
55. Freeman JG, Barton JR, Record CO. Haemodynamic responses to 1.25 and 2 mg of terlipressin intravenously in man. Aliment Pharmacol Ther 1988; 2: 361-7.
56. Ioannou GN, Doust J, Rockey DC. Systematic review: terlipressin in acute oesophageal variceal haemorrhage. Aliment Pharmacol Ther 2003; 17: 53-64.
57. Freeman JG, Cobden I, Record CO. Placebo-controlled trial of terlipressin (glypressin) in the management of acute variceal bleeding. J Clin Gastroenterol 1989; 11: 58-60.
58. D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 1999; 19: 475-505.
59. Freeman JG, Cobden I, Lishman AH, Record CO. Controlled trial of terlipressin ('Glypressin') versus vasopressin in the early treatment of oesophageal varices. Lancet 1982; 2: 66-8.
60. D'Amico G, Pietrosi G, Tarantino I, Pagliaro L. Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis: a Cochrane meta-analysis. Gastroenterology 2003; 124: 1277-91.
61. Escorsell A, Ruiz dA, Planas R, et al. Multicenter randomized controlled trial of terlipressin versus sclerotherapy in the treatment of acute variceal bleeding: the TEST study. Hepatology 2000; 32: 471-6.
62. Shawcross DL, Davies NA, Mookerjee RP, et al. Worsening of cerebral hyperemia by the administration of terlipressin in acute liver failure with severe encephalopathy. Hepatology 2004; 39: 471-5.
63. Hadengue A, Gadano A, Moreau R, et al. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 1998; 29: 565-70.
64. Guevara M, Gines P, Fernandez-Esparrach G, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998; 27: 35-41.
65. Brenner BM, Troy JL, Daugharty TM, Deen WM, Robertson CR. Dynamics of glomerular ultrafiltration in the rat. II. Plasma-flow dependence of GFR. Am J Physiol 1972; 223: 1184-90.
66. Arendshorst WJ, Gottschalk CW. Glomerular ultrafiltration dynamics: euvolemic and plasma volume-expanded rats. Am J Physiol 1980; 239: F171-F186.
67. Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008; 134: 1360-8.
68. Martin-Llahi M, Pepin MN, Guevara M, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008; 134: 1352-9.
69. Lenz K, Hortnagl H, Druml W, et al. Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis. Effects on renal hemodynamics and atrial natriuretic factor. Gastroenterology 1991; 101: 1060-7.
70. Guevara M, Gines P, Fernandez-Esparrach G, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998; 27: 35-41.
71. Gulberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 1999; 30: 870-5.
72. Gines P, Berl T, Bernardi M, et al. Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology 1998; 28: 851-64.
73. Haussinger D, Kircheis G, Fischer R, Schliess F, vom DS. Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema? J Hepatol 2000; 32: 1035-8.
74. Schliess F, Gorg B, Haussinger D. Pathogenetic interplay between osmotic and oxidative stress: the hepatic encephalopathy paradigm. Biol Chem 2006; 387: 1363-70.
75. Wu CC, Yeung LK, Tsai WS, et al. Incidence and factors predictive of acute renal failure in patients with advanced liver cirrhosis. Clin Nephrol 2006; 65: 28-33.
76. Londono MC, Guevara M, Rimola A, et al. Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology 2006; 130: 1135-43.
77. Guyader D, Patat A, Ellis-Grosse EJ, Orczyk GP. Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. Hepatology 2002; 36: 1197-205.
78. Ferguson JW, Therapondos G, Newby DE, Hayes PC. Therapeutic role of vasopressin receptor antagonism in patients with liver cirrhosis. Clin Sci (Lond) 2003; 105: 1-8.
79. Bosch-Marce M, Poo JL, Jimenez W, et al. Comparison of two aquaretic drugs (niravoline and OPC-31260) in cirrhotic rats with ascites and water retention. J Pharmacol Exp Ther 1999; 289: 194-201.
80. Jimenez W, Gal CS, Ros J, et al. Long-term aquaretic efficacy of a selective nonpeptide V(2)-vasopressin receptor antagonist, SR121463, in cirrhotic rats. J Pharmacol Exp Ther 2000; 295: 83-90.
81. Tsuboi Y, Ishikawa S, Fujisawa G, Okada K, Saito T. Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats. Kidney Int 1994; 46: 237-44.
82. Yamamura Y, Ogawa H, Yamashita H, et al. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol 1992; 105: 787-91.
83. Inoue T, Ohnishi A, Matsuo A, et al. Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis. Clin Pharmacol Ther 1998; 63: 561-70.
84. Decaux G. Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985. J Lab Clin Med 2001; 138: 18-21.
85. Gerbes AL, Gulberg V, Gines P, et al.Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003; 124: 933-9.
86. Wong F, Blei AT, Blendis LM, Thuluvath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 2003; 37: 182-91.
87. Thuluvath PJ, Maheshwari A, Wong F, et al. Oral V2 receptor antagonist (RWJ-351647) in patients with cirrhosis and ascites: a randomized, double-blind, placebo-controlled, single ascending dose study. Aliment Pharmacol Ther 2006; 24: 973-82.
88. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355: 2099-112.
89. Wong F, Gines P, Watson H, Kujundzic M, Angeli P, Horsmans Y. Effects of a selective vasopressin V2 receptor antagonist, Satavaptan (SR121463B), on recurrence of ascites after large volume paracentesis. Hepatology 2006; 44: 256A.
90. Gines P, Wong F, Milutinovic S, Ruiz del Arbol L, Olteanu D. Effects of satavaptan (SR121463B), a selective vasopressin V2 receptor antagonist, on serum sodium concentration and ascites in patients with cirrhosis and hyponatraemia. J Hepatol 2006; 44: S270.
91. Ali F, Guglin M, Vaitkevicius P, Ghali JK. Therapeutic potential of vasopressin receptor antagonists. Drugs 2007; 67: 847-58.
92. Kawano Y, Matsuoka H, Nishikimi T, Takishita S, Omae T. The role of vasopressin in essential hypertension. Plasma levels and effects of the V1 receptor antagonist OPC-21268 during different dietary sodium intakes. Am J Hypertens 1997; 10: 1240-4.
93. Clair MJ, King MK, Goldberg AT, et al. Selective vasopressin, angiotensin II, or dual receptor blockade with developing congestive heart failure. J Pharmacol Exp Ther 2000; 293: 852-60.
94. Chelarescu O, Chelarescu D, Stratan I, Filip C. Terlipressin influence in spontaneous bacterial peritonitis. J Hepatol 2004; 40: 67.
95. Kiszka-Kanowitz M, Henriksen JH, Hansen EF, Moller S, Bendtsen F. Effect of terlipressin on blood volume distribution in patients with cirrhosis. Scand J Gastroenterol 2004; 39: 486-92.
96. Cervoni JP, Lecomte T, Cellier C, et al. Terlipressin may influence the outcome of hepatorenal syndrome complicating alcoholic hepatitis. Am J Gastroenterol 1997; 92: 2113-4.
97. Ruiz-del-Arbol L, Monescillo A, Jimenez W, Garcia-Plaza A, Arroyo V, Rodes J. Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 1997; 113: 579-86.
98. Moreau R, Asselah T, Condat B, et al. Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study. Gut 2002; 50: 90-4.
99. Hollenberg SM, Broussard M, Osman J, Parrillo JE. Increased microvascular reactivity and improved mortality in septic mice lacking inducible nitric oxide synthase. Circ Res 2000; 86: 774-8.
100. Yamamoto K, Ikeda U, Okada K, Saito T, Shimada K. Arginine vasopressin inhibits nitric oxide synthesis in cytokine-stimulated vascular smooth muscle cells. Hypertens Res 1997; 20: 209-16.
101. Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997; 95: 1122-5.